Mazdutide vs Tirzepatide
Both are dual agonists that share GLP-1 receptor activity but differ in their second target: glucagon for mazdutide, GIP for tirzepatide.
Mazdutide
A once-weekly dual GLP-1 / glucagon-receptor agonist, first approved in China in 2025.
BEST STUDIED FOR
Incretin & metabolic
Read the cited profile →
Tirzepatide
Tirzepatide is a synthetic dual agonist of the GIP and GLP-1 incretin receptors.
BEST STUDIED FOR
Dual-agonist (GIP/GLP-1) metabolic research
FREE GIFTFree GHK-Cu 50 mg with every Tirzepatide 30mg vial and free GHK-Cu 100 mg with every Tirzepatide 60mg vial, until 15 Oct — one per vial, added automatically at checkout.
Side by side · to buy
Price, purity and dispatch
| Compare | Mazdutide | Tirzepatide30 mg · more sizes |
|---|---|---|
| Price | — | fromR1,399 |
| Cost per mg | — | R46.6 / mg |
| Purity (Janoshik) | — | 99.927%HPLC, published |
| Stock | — | Restocking |
| Dispatch | — | When restocked |
| Certificate | — | View CoA → |
| Literature | — | 3 papers → |
| Research focus | Incretin & metabolic | Dual-agonist (GIP/GLP-1) metabolic research |
| Read the cited profile | Notify me |
Prices are read live from the catalogue. Cost per mg is the vial price over its stated mg. Purity is shown only where the certificate is published. Every compound is supplied for laboratory research only.
SIDE BY SIDE
| Mazdutide | Tirzepatide | |
|---|---|---|
| The key difference | GLP-1 + glucagon | GLP-1 + GIP |
| Class | Incretin & metabolic | Incretin & metabolic |
| Mechanism | Like survodutide, mazdutide combines GLP-1 receptor agonism with glucagon-receptor agonism, the latter studied for energy expenditure and liver fat. | Tirzepatide is a synthetic dual agonist of the GIP and GLP-1 incretin receptors. |
| Status | Approved in China (2025) for weight management; phase 3 trials in obesity and type 2 diabetes, including a head-to-head versus dulaglutide. | An approved medicine (US/EU) for type 2 diabetes and obesity. |
| Reported safety signals | Trials report gastrointestinal events as most common; phase 1b work explored higher doses for tolerability. | Phase 3 trials reported mainly gastrointestinal adverse events (nausea, diarrhoea, vomiting). |
| A key study | A phase 3 placebo-controlled trial measured weight change with mazdutide in Chinese adults. (N Engl J Med 2025, PMID 40421736) | The discovery-to-proof-of-concept study characterising LY3298176 (tirzepatide) as a novel dual GIP/GLP-1 receptor agonist. (Mol Metab 2018, PMID 30473097) |
WHEN TO RESEARCH WHICH
This pair isolates the question of which second receptor — glucagon or GIP — adds more to GLP-1 agonism. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.
REFERENCES (PUBMED)
- [Mazdutide] Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight — N Engl J Med 2025. PMID 40421736
- [Mazdutide] Mazdutide: First Approval — Drugs 2025. PMID 41028652
- [Mazdutide] Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes — Nature 2026. PMID 41407860
- [Tirzepatide] LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept — Mol Metab 2018. PMID 30473097
- [Tirzepatide] Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes — N Engl J Med 2021. PMID 34170647
- [Tirzepatide] Tirzepatide Once Weekly for the Treatment of Obesity — N Engl J Med 2022. PMID 35658024
FREQUENTLY ASKED
What is the difference between Mazdutide and Tirzepatide?
Both are dual agonists that share GLP-1 receptor activity but differ in their second target: glucagon for mazdutide, GIP for tirzepatide.
What is the regulatory status of Mazdutide and Tirzepatide?
Mazdutide: Approved in China (2025) for weight management; phase 3 trials in obesity and type 2 diabetes, including a head-to-head versus dulaglutide. Tirzepatide: An approved medicine (US/EU) for type 2 diabetes and obesity.
What safety signals have been reported?
Mazdutide: Trials report gastrointestinal events as most common; phase 1b work explored higher doses for tolerability. Tirzepatide: Phase 3 trials reported mainly gastrointestinal adverse events (nausea, diarrhoea, vomiting).
Which studies is this comparison based on?
For Mazdutide: “Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight” (PMID 40421736); “Mazdutide: First Approval” (PMID 41028652); “Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes” (PMID 41407860). For Tirzepatide: “LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept” (PMID 30473097); “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes” (PMID 34170647); “Tirzepatide Once Weekly for the Treatment of Obesity” (PMID 35658024).
MORE COMPARISONS
All products supplied for research purposes only. Not for human consumption.
In stock · ships from South Africa
In stock now
Supplied for laboratory research only · not for human use